What is OS Therapies's EPS (basic)?

OS Therapies (OSTX) reported EPS (basic) of -$0.27 in Q1 2026.

How has OS Therapies's EPS (basic) changed year-over-year?

OS Therapies's EPS (basic) decreased by 50.0% year-over-year, from -$0.18 to -$0.27.

What does EPS (basic) mean?

Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

OS Therapies OSTX EPS (Basic)

EPS (Basic) at other companies

ImmunomeIMNM

-$0.48+7.7%

CTO

Citius Oncology, Inc.CTOR

-$0.27-145%

Avalo TherapeuticsAVTX

-$0.98+21.6%

Arcus BiosciencesRCUS

-$1.02+10.5%

ImmunityBio, Inc.IBRX

-$0.62-313%

WHW

Whitehawk Therapeutics, Inc. Common StockWHWK

-$0.32-117%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's EPS (basic)?: OS Therapies (OSTX) reported EPS (basic) of -$0.27 in Q1 2026.
How has OS Therapies's EPS (basic) changed year-over-year?: OS Therapies's EPS (basic) decreased by 50.0% year-over-year, from -$0.18 to -$0.27.
What does EPS (basic) mean?: Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.